Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Merck and Daiichi Sankyo voluntarily withdrew their FDA application for a lung cancer drug due to insufficient data, though trials continue.
Share
Why It Matters
Two drug companies stopped trying to get FDA approval for a new lung cancer medicine. They didn't have enough proof it works, but they keep testing it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.